GLP-1 medications like Ozempic and Wegovy are reshaping the pharmaceutical industry. This episode explores the financial side of the GLP-1 boom, from the competition between Eli Lilly and Novo Nordisk to rising demand, manufacturing challenges, and major investments. Discover what CPAs and finance professionals can learn about financial risks, capital allocation, and long-term business growth.
What you'll learn
Upon completion of this course, you will be able to:
Explain the development of GLP-1 medications and why demand has grown so rapidly.
Examine the business strategies of Eli Lilly and Novo Nordisk in responding to unprecedented demand.
Analyze how supply constraints, pricing, competition, and manufacturing capacity affect financial performance.
Explore the financial and strategic considerations associated with investing heavily in a rapidly growing product category.
Identify lessons CPAs can apply to forecasting, capital allocation, inventory management, and evaluating growth opportunities.
Quizzes and assessment
Complete all quizzes and the final assessment to earn CPE.
Locked
Final assessment
Enroll and complete the required learning to unlock your final assessment.
5 questions70% to passUnlimited attempts
On passing: 1.0 CPE and a certificate
Quizzes open automatically at the markers in your audio.
Course details
CPE
1.0
Field of study
Finance
Delivery method
Interactive Audio
Prerequisites
None
Advance preparation
None
Course level
Overview
Course content
51 min of audio · 2 quizzes · final assessment
Assessment
5 questions · 70% to pass · unlimited attempts
Completion deadline
365 days from enrollment
Registration
A Wisdify account, eligible subscription, and course enrollment are required.
PODCAST COURSE
